William Thomas Cash, MD, MSc

Research Program

Discovery and Developmental Therapeutics
Phone Number

404-785-0910
Email Address

thomas.cash@emory.edu

Biography

W. Thomas Cash, MD, MSc, is an associate professor in the Department of Pediatrics at Emory University School of Medicine. Dr. Cash is board certified in pediatric hematology/oncology. Dr. Cash is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute.

Education

Dr. Cash received his MD from University of Alabama School of Medicine in Birmingham, Alabama. He completed his residency in pediatrics at University of Arkansas for Medical Sciences/Arkansas Children's Hospital in Little Rock, Arkansas. He then obtained his MSc in clinical and translational research from Emory University School of Medicine in Atlanta, Georgia, where he also completed his fellowship in pediatric hematology oncology.

Titles & Roles

Associate Professor, Department of Pediatrics

Emory University School of Medicine

Professional Memberships

Dr. Cash is a diplomate of the American Board of Pediatric Hematology/Oncology and the American Board of Pediatrics. He holds professional memberships with American Society of Pediatric Hematology/Oncology, Children's Oncology Group and American Society of Clinical Oncology.

Research

Dr. Cash's research objectives stem from his clinical focus in treating pediatric solid tumor patients with recurrent and/or refractory disease. His broad objective is to identify novel therapeutic agents and to bring the most promising of these agents to clinical trials to improve the outcomes for pediatric patients with relapsed/refractory disease.

View Current Clinical Trials


Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Phase II Conditions Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Tumors (With PI Approval), Other SMARCA4-deficient Malignant Tumors (With PI Approval) Location Winship Cancer Institute
Losartan + Sunitinib in Treatment of Osteosarcoma Phase I Conditions Osteosarcoma Location Winship Cancer Institute
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Phase I Conditions Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm Location Winship Cancer Institute
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Phase III Conditions Ganglioneuroblastoma, Neuroblastoma Location Winship Cancer Institute
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase II Conditions Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Osteosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Refractory Childhood Malignant Germ Cell Tumor, Refractory Childhood Osteosarcoma, Refractory Childhood Rhabdomyosarcoma, Refractory Childhood Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Wilms Tumor Location Winship Cancer Institute
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Phase II Conditions Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor Location Winship Cancer Institute
Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors Phase I Conditions Cancer Location Winship Cancer Institute
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Phase II Conditions Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor Location Winship Cancer Institute
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options Phase I Conditions Solid Tumors, CNS Tumors Location Winship Cancer Institute
Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Phase I Conditions Diffuse Intrinsic Pontine Glioma, Brain Tumor, Recurrent, Solid Tumor, Recurrent, Neuroblastoma, Recurrent, Refractory, Ewing Sarcoma, Recurrent, Refractory, Rhabdomyosarcoma, Recurrent, Refractory, Osteosarcoma, Recurrent, Refractory, Rhabdoid Tumor, Recurrent, Refractory Location Winship Cancer Institute
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Phase II Conditions Cancer Location Winship Cancer Institute
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Phase III Conditions Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma Location Winship Cancer Institute
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma Phase III Conditions High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Phase III Conditions Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Phase I Conditions Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma Location Winship Cancer Institute

Title/Journal	Authors	Publication Date
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	T Cash, MD Krailo, AB Buxton, BR Pawel, JH Healey, O Binitie, KJ Marcus, HE Grier, PJ Grohar, DR Reed, AR Weiss, R Gorlick, KA Janeway, SG DuBois, RB Womer	20/10/2023
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors. Pediatric blood & cancer	T Cash, HC Jonus, M Tsvetkova, JH Beumer, A Sadanand, JY Lee, CJ Henry, D Aguilera, RD Harvey, KC Goldsmith	01/08/2023
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	BJ Lerman, Y Li, C Carlowicz, M Granger, T Cash, A Sadanand, K Somers, A Ranavaya, BD Weiss, M Choe, JH Foster, N Pinto, DA Morgenstern, MS Rafael, KA Streby, RN Zeno, R Mody, S Yazdani, AV Desai, ME Macy, S Shusterman, SM Federico, R Bagatell	20/01/2023
Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia. Cancer	PA Patel, NP DeGroote, K Jackson, T Cash, SM Castellino, P Jaggi, AJ Esbenshade, TP Miller	01/12/2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro-oncology	AV Desai, GW Robinson, K Gauvain, EM Basu, ME Macy, L Maese, NS Whipple, AJ Sabnis, JH Foster, S Shusterman, J Yoon, BD Weiss, MS Abdelbaki, AE Armstrong, T Cash, CA Pratilas, N Corradini, LV Marshall, M Farid-Kapadia, S Chohan, C Devlin, G Meneses-Lorente, A Cardenas, KE Hutchinson, G Bergthold, H Caron, E Chow Maneval, A Gajjar, E Fox	03/10/2022
A bridge over troubled water-Extending induction for high-risk neuroblastoma patients with poor end-of-induction response. Cancer	SM Federico, T Cash	01/08/2022
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). Pediatric blood & cancer	T Cash, E Fox, X Liu, CG Minard, JM Reid, AC Scheck, BJ Weigel, C Wetmore	01/09/2021
Routine Surveillance Imaging Is Associated with Improved Postrelapse Survival in Patients with Ewing Sarcoma. Journal of adolescent and young adult oncology	T Cash, EL Bettermann, S Mitchell, C McCracken, M Qayed, D Wolfe, A Alazraki, TA Olson, HM Katzenstein	01/06/2020
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer	RD Roberts, MM Lizardo, DR Reed, P Hingorani, J Glover, W Allen-Rhoades, T Fan, C Khanna, EA Sweet-Cordero, T Cash, MW Bishop, M Hegde, AR Sertil, C Koelsche, L Mirabello, D Malkin, PH Sorensen, PS Meltzer, KA Janeway, R Gorlick, BD Crompton	15/10/2019
Successful Use of Extracorporeal Life Support in a Hematopoietic Stem Cell Transplant Patient with Neuroblastoma. The journal of extra-corporeal technology	FZ Williams, A Vats, T Cash, JD Fortenberry	01/03/2018
A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	B Geoerger, F Bourdeaut, SG DuBois, M Fischer, JI Geller, NG Gottardo, A Marabelle, ADJ Pearson, S Modak, T Cash, GW Robinson, M Motta, A Matano, SG Bhansali, JR Dobson, S Parasuraman, SN Chi	15/05/2017
Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement. International journal of radiation oncology, biology, physics	MJ Ferris, H Danish, JM Switchenko, C Deng, BA George, KC Goldsmith, KJ Wasilewski, WT Cash, MK Khan, BR Eaton, N Esiashvili	15/03/2017
Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatric blood & cancer	T Cash, E McIlvaine, MD Krailo, SL Lessnick, ER Lawlor, N Laack, J Sorger, N Marina, HE Grier, L Granowetter, RB Womer, SG DuBois	01/10/2016
Use of portal pressure studies in the management of variceal haemorrhage. World journal of gastrointestinal endoscopy	J Addley, TC Tham, WJ Cash	16/07/2012